KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Notes Payables (2018 - 2024)

Exact Sciences has reported Notes Payables over the past 5 years, most recently at $249.2 million for Q4 2024.

  • Quarterly Notes Payables changed N/A to $249.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $249.2 million through Dec 2024, changed N/A year-over-year, with the annual reading at $249.2 million for FY2024, N/A changed from the prior year.
  • Notes Payables was $249.2 million for Q4 2024 at Exact Sciences, roughly flat from $249.0 million in the prior quarter.
  • Over five years, Notes Payables peaked at $313.0 million in Q2 2021 and troughed at $1.3 million in Q2 2020.
  • The 3-year median for Notes Payables is $24.6 million (2020), against an average of $121.8 million.
  • The largest YoY upside for Notes Payables was 23627.14% in 2021 against a maximum downside of 94.63% in 2021.
  • A 3-year view of Notes Payables shows it stood at $1.3 million in 2020, then changed by 0.0% to $1.3 million in 2021, then soared by 18789.54% to $249.2 million in 2024.
  • Per Business Quant, the three most recent readings for EXAS's Notes Payables are $249.2 million (Q4 2024), $249.0 million (Q3 2024), and $248.9 million (Q2 2024).